We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04580121




Registration number
NCT04580121
Ethics application status
Date submitted
1/10/2020
Date registered
8/10/2020
Date last updated
4/05/2021

Titles & IDs
Public title
A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
Scientific title
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid Leukemia
Secondary ID [1] 0 0
2020-000216-30
Secondary ID [2] 0 0
WP42004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - RO7283420
Treatment: Drugs - RO7283420
Treatment: Drugs - Tocilizumab
Treatment: Drugs - Dasatinib

Experimental: RO7283420 Part A - Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.

Experimental: RO7283420 Part B - Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A of RO7283420 once Q3W starting on C1D1 up to Cycle 6 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).

Experimental: RO7283420 Part C - Participants will receive the respective RP2D for Group I and Group II.


Treatment: Drugs: RO7283420
RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg.

Treatment: Drugs: RO7283420
RO7283420 at RP2D will be administered by IV infusion as per dosing schedule determined in Part B.

Treatment: Drugs: Tocilizumab
Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.

Treatment: Drugs: Dasatinib
Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily [BID] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants with Adverse Events (AEs)
Timepoint [1] 0 0
From baseline up to 9 months
Primary outcome [2] 0 0
Percentage of Participants with Dose-Limiting Toxicities (DLTs)
Timepoint [2] 0 0
From baseline up to 28 days
Secondary outcome [1] 0 0
Maximum Reduction (%) from Baseline in Blast Count in Peripheral Blood and/or Bone Marrow
Timepoint [1] 0 0
From baseline up to 7 months
Secondary outcome [2] 0 0
Percentage of Participants with >= 50% Reduction from Baseline in Blast Count in Peripheral Blood and/or Bone Marrow
Timepoint [2] 0 0
From baseline up to 7 months
Secondary outcome [3] 0 0
Number of MRD (Measurable Residual Disease) Negative Participants over time According to Local MRD Assessment
Timepoint [3] 0 0
From baseline up to 7 months
Secondary outcome [4] 0 0
Area Under the Curve (AUC) of RO7283420
Timepoint [4] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [5] 0 0
Maximum Concentration (Cmax) of RO7283420
Timepoint [5] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [6] 0 0
Minimum Concentration (Cmin) of RO7283420
Timepoint [6] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [7] 0 0
Clearance (Cl) of RO7283420
Timepoint [7] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [8] 0 0
Volume (V) of RO7283420
Timepoint [8] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [9] 0 0
Half-life (T1/2) of RO7283420
Timepoint [9] 0 0
Day 1, 2, 3, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 of Cycle 2-9, at end of treatment visit (28 days after the last dose of RO7283420)
Secondary outcome [10] 0 0
Incidence and Titer of Anti-drug Antibodies (ADA) against RO7283420
Timepoint [10] 0 0
Day 1, 8, 15 of Cycle 1 (each cycle is 21 days); Day 1 and 8 of Cycle 2, Day 1 of Cycle 3-9, at end of treatment visit (28 days after the last dose of RO7283420)

Eligibility
Key inclusion criteria
- With confirmed diagnosis of primary or secondary AML according to WHO classification
2016, with measurable disease. Eligible participants need to have received
standard-of-care (SOC) and have no other SOC options available. Participants who are
not willing to receive SOC will be not eligible. Two groups of participants (Group I
and Group II) will be included.

- Participants who have received hematopoietic stem cell transplant (HSCT) must have the
HSCT performed = 28 days prior to screening, having demonstrated hematological
engraftment and do not have an active Graft versus Host disease

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Peripheral blast counts =< 20,000/mm3 on Cycle 1 Day 1 prior to the first dosing

- Confirmed genotype of HLA-A*02

- Adequate renal and liver test results

- Male or female participants agree to use contraception and the abstinence requirements
to prevent exposure of an embryo to the study treatment
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Acute promyelocytic leukemia (APL)

- Core Binding Factor (CBF)-AML Note: participants with r/r CBF-AML after at least 2
salvage attempts can be enrolled into the study

- Group II only: participants with normal karyotype and a favorable molecular profile
according to ELN guideline 2017

- Participants with active bacterial, fungal or viral infection considered by the
Investigator to be clinically uncontrolled or of unacceptable risk upon the induction
of neutropenia (i.e. participants who are or should be on antimicrobial agents for the
treatment of active infection)

- Glomerular proteinuria (Grade >= 2) with presence of transferrin and/or IgG in the
urine

- Another primary malignancy (other than AML) that requires active therapy. Adjuvant
hormonal therapy is allowed

- History of autoimmune disease

- Clinical evidence or history of central nervous system (CNS) leukemia

- Presence of isolated extramedullary disease at screening

- Current or past history of CNS disease, such as stroke, CNS inflammation, epilepsy,
CNS vasculitis, or neurodegenerative disease

- Participants who have a history of clinically significant liver disease, including
liver cirrhosis (e.g. Child-Pugh class B and C) or participants who have a history of
active or chronic infectious hepatitis unless serology demonstrates clearance of
infection

- Participants who might refuse to receive blood products and/or have known
hypersensitivity to any of the components of RO7283420

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Peter MacCallum Cancer Centre; Medical Oncology - Melbourne
Recruitment hospital [2] 0 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment postcode(s) [2] 0 0
3124 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Missouri
Country [3] 0 0
United States of America
State/province [3] 0 0
Texas
Country [4] 0 0
Canada
State/province [4] 0 0
Ontario
Country [5] 0 0
Denmark
State/province [5] 0 0
København Ø
Country [6] 0 0
France
State/province [6] 0 0
Marseille
Country [7] 0 0
France
State/province [7] 0 0
Pessac
Country [8] 0 0
Germany
State/province [8] 0 0
Dresden
Country [9] 0 0
Germany
State/province [9] 0 0
München
Country [10] 0 0
Italy
State/province [10] 0 0
Lombardia
Country [11] 0 0
Italy
State/province [11] 0 0
Toscana
Country [12] 0 0
Spain
State/province [12] 0 0
Barcelona
Country [13] 0 0
Spain
State/province [13] 0 0
Madrid
Country [14] 0 0
Spain
State/province [14] 0 0
Valencia
Country [15] 0 0
Taiwan
State/province [15] 0 0
Taichung
Country [16] 0 0
Taiwan
State/province [16] 0 0
Tainan
Country [17] 0 0
Taiwan
State/province [17] 0 0
Taipei
Country [18] 0 0
United Kingdom
State/province [18] 0 0
Manchester
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Oxford
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability,
pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will
be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the
maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).
Trial website
https://clinicaltrials.gov/show/NCT04580121
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: WP42004 www.roche.com/about_roche/roche_worldwide.htm
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S. and Canada)
Fax 0 0
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04580121